Technical Analysis for GHDX - Genomic Health, Inc.

Grade Last Price % Change Price Change
grade F 63.44 -0.69% -0.44
GHDX closed down 0.69 percent on Thursday, November 7, 2019, on 19.85 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical GHDX trend table...

Date Alert Name Type % Chg
Spinning Top Other 0.00%
Volume Surge Other 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness -0.69%
Stochastic Reached Oversold Weakness -0.69%

Older signals for GHDX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company provides the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit. It also offers the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer. Genomic Health, Inc. was founded in 2000 and is headquartered in Redwood City, California.
Medicine Cancer Healthcare Clinical Medicine Treatment Of Cancer Chemotherapy Breast Cancer Cancer Treatment Colorectal Cancer
Is GHDX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 86.7
52 Week Low 50.77
Average Volume 631,490
200-Day Moving Average 67.2359
50-Day Moving Average 69.7366
20-Day Moving Average 67.8495
10-Day Moving Average 66.502
Average True Range 1.727
ADX 18.46
+DI 15.9196
-DI 35.0708
Chandelier Exit (Long, 3 ATRs ) 66.269
Chandelier Exit (Short, 3 ATRs ) 67.921
Upper Bollinger Band 72.1056
Lower Bollinger Band 63.5934
Percent B (%b) -0.02
BandWidth 12.545708
MACD Line -1.2924
MACD Signal Line -0.899
MACD Histogram -0.3934
Fundamentals Value
Market Cap 2.19 Billion
Num Shares 34.5 Million
EPS -0.15
Price-to-Earnings (P/E) Ratio -422.93
Price-to-Sales 3.41
Price-to-Book 6.72
PEG Ratio -149.73
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 66.19
Resistance 3 (R3) 66.26 65.41 65.73
Resistance 2 (R2) 65.41 64.71 65.38 65.57
Resistance 1 (R1) 64.43 64.28 64.01 64.36 65.42
Pivot Point 63.58 63.58 63.37 63.55 63.58
Support 1 (S1) 62.60 62.88 62.18 62.53 61.46
Support 2 (S2) 61.75 62.45 61.72 61.31
Support 3 (S3) 60.77 61.75 61.15
Support 4 (S4) 60.70